Materiały źródłowe

• #1 RSV (Respiratory Syncytial Virus) Immunizations | CDC

  https://www.cdc.gov/vaccines/vpd/rsv/index.html

  Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious. Infants and older adults are more likely to develop severe RSV and need hospitalization. Vaccines are available to protect older adults from severe RSV. Vaccines for pregnant women or monoclonal antibody products are available to protect infants and young children from severe RSV. […] RSV Vaccine Guidance for Pregnant Women […] RSV Vaccine Guidance for Older Adults.

• #1 Healthcare Providers: RSV Immunization for Infants and Young Children | CDC

  https://www.cdc.gov/vaccines/vpd/rsv/hcp/child.html

  Nirsevimab is an injectable monoclonal antibody that prevents severe RSV disease in infants and young children. Monoclonal antibodies do not activate the immune system, as would occur with infection or vaccination (active immunization). Rather, the antibodies themselves protect against disease (i.e., passive immunization). […] Nirsevimab does not provide long-term immunity to RSV disease but provides protection to infants when they are most at risk of getting severe RSV disease. […] Nirsevimab can be administered without regard to timing of routine childhood vaccines. This includes simultaneous administration (i.e., same clinic day) with vaccine products. No interval between nirsevimab and live vaccines (such as MMR and Varicella) is necessary. […] Nirsevimab is not expected to interfere with the immune response to vaccine products.

• #1 Nirsevimab Frequently Asked Questions

  https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-frequently-asked-questions/?srsltid=AfmBOoq9oivX3RToAGwVYvTok00T71NZ7jmFyLjlFwUYjc5IyEzZwTHx

  Nirsevimab is a monoclonal antibody product that is a passive immunization. While not technically a vaccine in a traditional sense (active immunization), it is being used in a manner similar to routine childhood vaccines and may be referred to as a vaccine by some entities. Nirsevimab confers long-lasting protection from RSV, with protection expected to last at least 5 months (about the length of a typical RSV season). Nirsevimab is part of the Vaccines for Children program. […] Protection is expected to last at least 5 months, about the length of an RSV season and is expected to reduce the risk of severe RSV disease by about 80%. Data from the 2023-2024 RSV season show that nirsevimab was effective against RSV-associated emergency department encounters and hospitalization among infants in their first RSV season. Specifically, data from the VISION Multi-Site Network of Electronic Health Records of 127 emergency departments and 107 hospitals showed nirsevimab was 77% effective at preventing RSV-associated ED encounters and 98% effective at preventing RSV-associated hospitalization. […] Nirsevimab has not been studied as a treatment in infants with RSV and is not licensed for treatment of RSV disease. Nirsevimab should be given prior to onset of the RSV season or as soon as possible after birth for infants born during the season to prevent severe RSV disease.

• #1 Should You Get an RSV Vaccine? > News > Yale Medicine

  https://www.yalemedicine.org/news/should-you-get-an-rsv-vaccine

  ABRYSVO is also approved for administering to pregnant women ahead of the RSV season to provide them with antibodies they could pass along to the fetus and protect their newborns from birth to 6 months of age from severe RSV. […] Both the AREXVY and ABRYSVO vaccines for older adults use traditional platforms similar to a flu shot. […] The third vaccine, mRESVIA, from Moderna, uses an mRNA platform, similar to the company’s COVID vaccine. […] AREXVY was the first to receive Food and Drug Administration (FDA) approval in May 2023 based on data from a trial conducted by the company in the U.S. and internationally. […] ABRYSVO, also approved in May 2023, showed an efficacy of almost 89% against LRTD involving at least three symptoms in the first year after vaccination. […] mRESVIA, was approved in May 2024 after Moderna provided trial clinical trial data showing an efficacy against LRTD of 83.7%.

• #1 New Monoclonal Antibody and Vaccine Can Protect Kids from RSV > News > Yale Medicine

  https://www.yalemedicine.org/news/new-rsv-monoclonal-antibody-vaccine-for-kids

  Nirsevimab is a monoclonal antibody (designed by pharmaceutical companies Sanofi and AstraZeneca), which was given an FDA Fast Track designation, a process designed to expedite drugs to treat serious conditions and fill unmet medical needs. Its a preventive option that mimics the immune systems ability to fight off invaders, such as viruses, providing an extra layer of defense against RSV, according to the CDC. (It is not intended to treat patients already sick with the virus.) […] A vaccine causes your body to produce antibodies to protect you against whatever virus the vaccine is targeting, Dr. Murray says. The monoclonal antibody bypasses that step. […] Abrysvo, developed by Pfizer, is approved for injection into the muscle to give pregnant individuals antibodies against RSV that they would pass along to the fetus—their newborn baby would be protected for the first six months of life. The vaccine for pregnant women is administered seasonally, from September to January to provide protection of newborns when RSV infection is expected to be at its highest, between October and March. […] Abrysvo has been shown to reduce the risk of RSV hospitalization for babies by 57% in the first six months after birth, according to the CDC.

• #1 RSV Vaccine: What It Is, Who Should Get It, Cost

  https://www.everydayhealth.com/lung-respiratory/respiratory-syncytial-virus-vaccine/

  In a study of pregnant individuals who received Abrysvo, newborns had nearly an 82 percent reduced risk of severe lower respiratory tract infection within 90 days after birth if their mother had been vaccinated. […] The FDA has deemed RSV vaccination to be both safe and effective after an evaluation of data from clinical trials. […] The federal Vaccine Adverse Event Reporting System recorded about 10.6 million adults ages 60 years and older receiving a recommended RSV vaccine between August 4, 2023 and March 30, 2024. […] The data included 11 reports of GBS in those who received Arexvy and 17 cases of GBS among those who received Abrysvo. […] The Takeaway: RSV vaccines can prevent severe respiratory illness in infants (through a vaccination of the mother), people ages 75 and older, and those ages 60 to 74 with certain underlying conditions. […] There are three RSV vaccine brands. The CDC does not recommend one over the other for older people, although Abrysvo is the only approved maternal vaccine. […] The FDA has deemed all these vaccines to be safe and effective based on data from clinical trials.

• #1 Should You Get an RSV Vaccine? > News > Yale Medicine

  https://www.yalemedicine.org/news/should-you-get-an-rsv-vaccine

  In September 2023, the CDC approved ABRYSVO on a seasonal basis to provide pregnant women with antibodies they could pass along to the fetus and protect their newborn babies from birth to 6 months of age from severe RSV. […] The vaccine is available from September to January to provide protection of newborns when infection rates are expected to be at their highest, between October and March. […] ABRYSVO has been shown to reduce the risk of RSV hospitalization for babies by 57% in the first six months after birth, according to the CDC. […] Nirsevimab, which was developed by Sanofi and AstraZeneca, is given in a single injection to the thigh. […] A Phase 3 clinical trial showed that nirsevimab reduced RSV-triggered lower respiratory tract infections serious enough to require medical care by 76.4% and cut RSV hospitalizations in healthy full-term and near-full-term infants by 76.8%.

• #1 The New RSV Shot: 6 Must-Knows for Parents | Connecticut Children’s

  https://www.connecticutchildrens.org/growing-healthy/rsv-monoclonal-antibody

  Fortunately, the shot starts working right away and will protect them through the winter months. […] Yes. There is a different vaccine, also new, recommended for pregnant women from 32-36 weeks’ gestation. This is a traditional vaccine (AMBBRYSVO) that induces protective antibodies against RSV in the mother, that are transferred through the placenta to the developing baby. These babies are born immune to RSV and usually do not need the monoclonal antibody vaccine.

• #1 A new vaccine is here to protect you and your loved ones from RSV this winter | NIH MedlinePlus Magazine

  https://magazine.medlineplus.gov/article/a-new-vaccine-is-here-to-protect-you-and-your-loved-ones-from-rsv-this-winter

  Adults ages 65 and older are at increased risk for RSV infection. […] In the spring of 2024, FDA licensed a new RSV vaccine, called MRESVIA, for adults 60 years of age and older. There are now three RSV vaccines recommended by the Centers for Disease Control and Prevention (CDC) for older adults: the other two are ABRYSVO and AREXVY. […] The CDC recommends everyone ages 75 and older (and adults ages 60 to 74 who are at increased risk of severe infection) get an RSV vaccine. Pregnant people during their 32nd through 36th week of pregnancy are also advised to get the ABRYSVO vaccine. […] RSV vaccines are usually covered by private health insurance, the Childrens Health Insurance Program, Medicare Part D, Medicaid, and TRICARE for military.

• #1 RSV Vaccine: What It Is, Who Should Get It, Cost

  https://www.everydayhealth.com/lung-respiratory/respiratory-syncytial-virus-vaccine/

  In May 2023, Arexvy, from GSK, became the first vaccine approved by the U.S. Food and Drug Administration (FDA) to fight RSV, using an inactivated preF protein combined with an adjuvant (an ingredient that helps create a stronger immune response). […] Abrysvo, from Pfizer, also received FDA approval in May 2023. Abrysvo does not use an adjuvant, but unlike Arexvy it contains the preF protein from both RSV A and B. […] While Arexvy and Abrysvo utilize a traditional vaccination method similar to the kind used for the flu shot, mRESVIA, from Moderna, relies on mRNA, a technology like the kind used for the companys COVID-19 shot. […] The Centers for Disease Control and Prevention (CDC) recommends the RSV vaccine for the following groups. […] The CDC advises eligible older adults to receive whichever brand of RSV vaccine is available, and doesnt recommend one type over another.

• #1 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  CDC recommends a single dose of RSV vaccine for older adults to help prevent serious RSV infection and hospitalization. […] Currently, CDC recommends only a single dose of RSV vaccine for all adults ages 75 and older and for adults ages 6074 with increased risk of severe RSV disease. […] The RSV vaccine is not currently an annual vaccine, meaning eligible adults do not need to get a dose every RSV season. […] RSV vaccines can be coadministered with other adult vaccines during the same visit. […] Adverse events after RSV vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS), even if it is not clear that the vaccine caused the adverse event. […] In studies of the real-world effectiveness of Arexvy during the 20232024 RSV season, Arexvy was approximately 77% effective in preventing RSV-associated emergency department encounters and 83% effective in preventing RSV-associated hospitalizations in adults 60 and older.

• #1 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  In studies of the real-world effectiveness of Abrysvo during the 20232024 RSV season, Abrysvo was approximately 79% effective in preventing RSV-associated emergency department encounters and 73% effective in preventing RSV-associated hospitalizations in adults 60 and older. […] In this trial, efficacy of a single dose of mResvia against symptomatic RSV was approximately 80% during the first 4 months following vaccination and approximately 56% during the first 12 months after vaccination.

• #1 RSV Vaccines Are Now Available – Allergy & Asthma Network

  https://allergyasthmanetwork.org/news/rsv-vaccine-asthma/

  mRESVIA clinical trials involved 37,000 adults ages 60+ years of age from 22 countries. The vaccine proved to be 83.7% effective against LRTD from RSV. It showed continued protection approximately 8.6 months after the dose. […] Clinical trials of each vaccine indicate that protection should last an entire RSV season, which is about 6-8 months. The vaccines could potentially provide protection for up to a year.

• #1 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  One dose of RSV vaccine provides protection against RSV disease in adults ages 60 years and older for at least two years. […] Based on the available data, ACIP and CDC continue to conclude that the benefits of RSV vaccination, in terms of preventable hospitalizations and deaths, outweigh the potential risk for GBS, among adults ages 75 years and older and among adults ages 60-74 years at increased risk of severe RSV disease.

• #1 RSV vaccines: Questions patients may have and how to answer | American Medical Association

  https://www.ama-assn.org/delivering-care/public-health/rsv-vaccines-questions-patients-may-have-and-how-answer

  Flu, COVID-19 and RSV vaccines may be given at the same visit. […] As with other vaccines, patients can expect some side effects from RSV vaccination. Some of the common side effects include fatigue, fever, headache, muscle or joint pain, nausea and diarrhea. […] Two immunization products are available for the prevention of severe RSV disease in infants. The maternal RSV vaccine (Pfizer’s Abrysvo) is given during weeks 32 through 36 of pregnancy during September through January in most of the U.S. Maternal antibodies protect the baby against RSV for approximately 6 months after birth. […] Nirsevimab is a single shot that is long lasting and can be given with other age-appropriate childhood vaccines. […] For infants born during or entering their very first RSV season, nirsevimab was 79% effective against RSV medically attended lower respiratory tract illness and 80% effective at preventing hospitalization. […] Both vaccines for older adults are also extremely effective at preventing serious illness from RSV infection. […] Most private health insurers must cover these immunization products without cost sharing. Medicare Part D covers all vaccines that the ACIP recommends, including vaccine for RSV.

• #1 Respiratory Syncytial Virus Prefusion F (RSVPreF3) Vaccine – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK594261/

  The RSVPreF3 and RSVPreF vaccines stimulate the humoral and cellular immune responses and provide immunity against RSV by targeting the pre-F forms of the F proteins present on the surface of RSV subgroups A and B. […] The vaccines stimulate the production of neutralizing antibodies that recognize and bind to the pre-F protein, blocking viral attachment and fusion with host cells. […] The AS01 adjuvant contained in the RSVPreF3 vaccine is a liposomal formulation that combines 2 immunostimulants that are QS-21, extracted from the bark of the Quillaja saponaria tree, and MPL, a synthetic derivative of bacterial lipopolysaccharide. […] RSVPreF3 and RSVPreF vaccines are important new tools to reduce morbidity and mortality caused by RSV among older adults and infants.

• #1 The RSV roadmap in children: Lessons learned, paths forward | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/91/9_suppl_1/S19

  The recognition that the prefusion conformation of the F glycoprotein generates more potent neutralizing antibodies became a significant step forward in RSV vaccine development. Considerable progress has been made focusing on vaccine candidates targeting this prefusion form. In 2023, data on 2 prefusion vaccines to prevent disease in adults was published by GSK (RSVPreF3 OA) and Pfizer (RSVpreF). […] Furthermore, to prevent severe RSV disease in newborns while averting the risk of ERD, maternal vaccination compared with placebo was evaluated in 2 studies. […] A recent phase 3 trial on RSV prefusion F protein-based maternal vaccine from GSK showed a vaccine efficacy of 65.5% for medically assessed RSV-associated LRTD and 69.0% for severe medically assessed RSV-associated LRTD. […] The significant RSV morbidity and mortality prompted trials of multiple therapeutic strategies to treat active disease. Beyond standard supportive care, treatment modalities for RSV bronchiolitis may be categorized as RSV nonspecific and RSV specific.

• #1 RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults | Respiratory Therapy

  https://respiratory-therapy.com/disorders-diseases/infectious-diseases/rsv/rsv-vaccine-effectiveness-lower-immunocompromised-older-adults/

  We found that on average, older adults who are immunocompromised developed fewer antibodies against RSV following vaccination as compared with the very strong responses for healthy people over age 60 seen in the clinical trials used to validate the vaccines, says study lead author Andrew Karaba, MD, PhD, assistant professor of medicine at the Johns Hopkins University School of Medicine, in a release. […] When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the group receiving the adjuvanted vaccine tended to have higher levels of RSV-neutralizing, anti-pre-fusion F antibodies, says Werbel in a release. So, adjuvant-enhanced vaccines as a means of improving immune response in people who are immunocompromised merits further investigation in larger, more comprehensive studies.

• #1 RSV vaccine: new protection options | Northwell Health

  https://www.northwell.edu/news/insights/rsv-vaccine-for-adults-pregnant-women

  mRESVIA, by contrast, is a messenger RNA (mRNA) vaccine. This means that it teaches your body how to make a protein that is on the surface of RSV. […] Another recently approved preventive treatment can also provide protection for infants against serious RSV disease. Called nirsevimab (Beyfortus), its a monoclonal antibody. […] Nirsevimab is only given to infants under 8 months between October 1 and March 31, coinciding with RSV season. […] Overall, Dr. Kainth considers the RSV treatments revolutionary and is confident that they will leave hospitals well-equipped to handle the upcoming season: We think theyll lead to a massive reduction in the number of cases of RSV. They’re going to change the winter season for babies everywhere.

• #1 Update: What RSV preventatives mean for those with PI | Immune Deficiency Foundation

  https://primaryimmune.org/resources/news-articles/update-what-rsv-preventatives-mean-those-pi

  Based on these trials, the CDCs Advisory Committee on Immunization Practices (ACIP) recommends that everyone 75 and older receive an RSV vaccine in late summer or early fall before RSV season begins. […] At this time, whether individuals with PI produce a protective response to the RSV vaccines is unknown. […] Two passive forms of immunity, which do not rely on an individuals immune response, are now available to protect infants: maternal vaccination with Abrysvo and nirsevimab, a long-lasting monoclonal antibody made by AstraZeneca and Sanofi under the trade name Beyfortus. […] In the Abrysvo maternal vaccination trial, vaccination at 24-36 weeks of pregnancy was 81.8% effective in preventing severe RSV in newborns from birth through 6 months of age. […] Nirsevimab is a monoclonal antibody that targets the same RSV surface protein as palivizumab and all three vaccines, blocking RSVs ability to infect human cells. […] Talk to your doctor to see if your child should receive the antibody prior to their second RSV season.

• #1 New vaccines and antibody treatment for RSV | Baptist Health | Jacksonville, FL

  https://www.baptistjax.com/juice/stories/community-health/rsv-vaccine-antibody-treatment

  New tools to kick the sick, from vaccines to antibodies. […] In mid-July, the U.S. Food and Drug Administration (FDA) approved a new monoclonal antibody injection to prevent RSV in babies and certain toddlers. Just two months earlier, the FDA gave the green light to two RSV vaccines for adults 60 and older. […] The monoclonal antibody injection known as Beyfortus can be given to newborns and infants under 8 months old entering their first RSV season. […] Monoclonal antibodies provide immediate and short-term protection, explained Shalika Katugaha, MD, system director of Infectious Diseases for Baptist Health. […] Vaccines work differently than monoclonal antibodies, said Dr. Katugaha. The RSV vaccines introduce an inactivated protein into the body that imitates the virus. The body then produces antibodies to protect the person from RSV infection. Vaccines train the immune system and boost long-term immunity.

• #1 Emerging Vaccine for Respiratory Syncytial Virus Treatment

  https://www.delveinsight.com/blog/respiratory-syncytial-virus-treatment

  Respiratory syncytial virus treatment is majorly supportive, with no approved drug for adults; in infants, Ribavirin and Synagis (palivizumab) were approved by the US FDA for respiratory syncytial virus treatment. […] After tremendous hard work, Sanofi and AstraZenecas Beyfortus (nirsevimab) got approved by the European Union to prevent RSV lower respiratory tract disease in newborns and infants. The respiratory syncytial virus vaccine addressed the challenges which were there with palivizumab. […] A single dose of Beyfortus is required for the entire RSV season, making it a more convenient option than Synagis, which requires monthly administration for the entire RSV season. […] To address these challenges, big pharma companies such as GSK and Pfizer are soon bringing the first respiratory syncytial virus vaccine to the older adult population.

• #1 RSV Vaccine: What It Is, Who Should Get It, Cost

  https://www.everydayhealth.com/lung-respiratory/respiratory-syncytial-virus-vaccine/

  The FDA has approved only one maternal RSV vaccine, Abrysvo. The pregnant persons immune system creates antibodies that get shared with the fetus, protecting a baby during the first six months of life when the risk of an infection becoming severe is highest. […] The CDC recommends vaccination in late summer or early fall, before respiratory virus season kicks in. […] The effectiveness of the RSV vaccine depends on the age of the recipient and the type of vaccine. […] The CDC says that studies of the real-world effectiveness of Arexvy during the 20232024 respiratory virus season showed the vaccine to be about 77 percent effective in preventing RSV-associated emergency room visits and 83 percent effective in preventing RSV-associated hospitalizations in adults 60 and older. […] Abrysvo was found to be about 79 percent effective in preventing RSV-associated emergency room visits and 73 percent effective in preventing RSV-related hospitalizations in adults 60 and older.

• #1 Large, real world data analysis finds RSV vaccine 80% effective

  https://www.regenstrief.org/article/multi-state-study-finds-rsv-vaccine-highly-effective/

  A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV short for respiratory syncytial virus vaccine. […] RSV vaccination provided approximately 80 percent protection against severe disease and hospitalization, Intensive Care Unit admission and death due to a respiratory infection as well as similar protection against less severe disease in adults who visited an emergency department but did not require hospitalization, ages 60 and older. […] The bottom line is that using real world data from electronic medical records routinely captured in care for people from diverse walks of life, we found that having the vaccine was highly protective against hospitalization, severe illness and death. […] Studies like this one are critical to understanding the effects of prevention techniques like vaccination. The annual cost of RSV hospitalization for adults in the U.S. is estimated to be between $1.2 and $5 billion. Preventing up to 80 percent of hospitalizations could result in major savings for consumers and the health system.

• #1 RSV Vaccine Program for Seniors Cut Hospitalizations by 62% | RT

  https://respiratory-therapy.com/disorders-diseases/infectious-diseases/rsv/rsv-vaccine-program-for-seniors-cut-hospitalizations-by-62/

  RSV vaccination program cut hospital admissions for a respiratory syncytial virus among seniors in Scotland by nearly two-thirds. […] A study from the University of Strathclyde and Public Health Scotland (PHS) found a 62% reduction in RSV-related hospitalizations among vaccinated older adults after the program launched in August 2024. […] The RSV vaccine offers long-term protection, benefiting older adults and newborns. Health officials encourage continued high uptake to prevent serious respiratory illnesses. […] The new study, published in The Lancet Infectious Diseases, is the first to give evidence of the impact of the RSV vaccination program and underlines the importance of older adults coming forward for their vaccine. One dose of the RSV vaccine offers multi-year protection and the results of this study show that, in the first year alone, the program has reduced serious illness among older adults.

• #1 What To Know About the RSV Vaccines: Who Can Get It, Side Effects, Availability at MSK | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/news/what-to-know-about-rsv-vaccines-who-can-get-it-side-effects-availability-at-msk

  Everyone age 60 and older who is at risk for getting very sick from RSV can get vaccinated, after talking with their doctor. […] People age 60 and older can get an RSV vaccine after talking with their doctor to see if its right for them. People younger than age 60, including people with cancer, are not eligible for the vaccine. […] The vaccines work very well. Both vaccines are more than 85% effective at preventing lower respiratory tract disease caused by RSV. […] RSV vaccines are safe for people with cancer who are eligible to get the shot. The vaccines are non-live vaccines that contain a part of the RSV virus (called a protein). The vaccine does not contain a whole virus or a live virus. The RSV vaccine cannot cause an infection in people with a weakened immune system. […] The vaccines made by GSK and Pfizer have similar side effects. Most common side effects are mild and go away after a few days. People who had the vaccines reported: Pain where they get the shot, Fatigue (feeling more weak or tired than usual), Headache, Muscle pain. […] Yes, the RSV vaccine is available for our patients. Ask a member of your care team for more information.

• #1 Respiratory Syncytial Virus (RSV): The Disease, Vaccines & Monoclonal Antibody | Children’s Hospital of Philadelphia

  https://www.chop.edu/vaccine-education-center/vaccine-details/rsv-vaccine-monoclonal-antibody

  Yes. Babies who get nirsevimab are less likely to require medical intervention for an RSV infection, including going to the emergency room, being hospitalized, ending up in the intensive care unit or needing oxygen. […] The RSV vaccine for adults can cause mild side effects. On the other hand, RSV typically hospitalizes between 60,000-160,000 adults and kills up to 10,000 people each year. […] The RSV vaccine for pregnant people can cause mild side effects. The vaccination benefits the baby from the time of delivery through their first RSV season. […] The RSV monoclonal antibody for infants can cause mild side effects, including injection site reactions and, for some, a rash.

• #1 RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults | Respiratory Therapy

  https://respiratory-therapy.com/disorders-diseases/infectious-diseases/rsv/rsv-vaccine-effectiveness-lower-immunocompromised-older-adults/

  RSV Vaccine Effectiveness Lower in Immunocompromised Older AdultsRSV Vaccine Effectiveness Lower in Immunocompromised Older Adults […] Weaker Vaccine Response: A Johns Hopkins study found that older adults with weakened immune systems, especially organ transplant recipients, show a significantly lower response to RSV vaccines compared to healthy older adults. […] Variability in Immunity: The antibody response to the vaccines varied widely among immunocompromised individuals, with some showing strong immune responses while others barely reacted to the vaccine. […] Adjuvant-Enhanced Vaccine Advantage: Participants who received the adjuvanted RSV vaccine (Arexvy) showed higher levels of RSV-neutralizing antibodies compared to those who received the non-adjuvanted version (Abrysvo), suggesting that adjuvants could enhance immune response in immunocompromised individuals.

• #1 The RSV Vaccine for Cancer Patients: What You Need to Know

  https://blog.dana-farber.org/insight/2025/01/the-rsv-vaccine-for-cancer-patients-what-you-need-to-know/

  RSV vaccines are available for: […] Adults over age 60 who are at an elevated risk for severe RSV, including those with moderate or severe immunocompromising conditions (e.g., active treatment with cancer chemotherapeutic agents, receipt of CAR-T or hematopoietic cell transplant, hematologic malignancies, receipt of solid organ transplant). […] The RSV vaccine is safe for people with cancer. Vaccinations are an essential part of care for people with cancer because they often have weakened immune systems and therefore are more likely to be at risk of severe infections from viruses like RSV. […] Dana-Farber recommends that all patients, including cancer survivors and active patients undergoing therapy who are over age 60, get vaccinated for RSV. […] Dana-Farber also recommends that certain individuals with immunocompromising conditions who are 18 to 59 years old should get the RSV vaccine, such as those undergoing HCT or treatments for hematologic malignancies. […] For Dana-Farber transplant and cellular therapy patients, we recommend considering vaccination once 100 days have elapsed from transplant or cellular therapy.

• #1 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  CDC recommends everyone ages 75 and older get an RSV vaccine. […] CDC recommends adults ages 60-74 who are at increased risk of severe RSV disease get an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine. If you have received an RSV vaccine already (including last year), you should not get another RSV vaccine at this time. […] The RSV vaccine is given as a single dose. […] CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60-74 years who are at increased risk of severe RSV. […] The RSV vaccine is not currently an annual vaccine. Protection from an RSV vaccine lasts more than one year. This means that if you have received an RSV vaccine already (including last year), you should not get another RSV vaccine at this time. […] If you haven’t gotten an RSV vaccine yet, you can get one at any time, but the best time to get vaccinated is in late summer and early fall before RSV usually starts to spread in the community.

• #1 RSV Immunization Guidance for Infants and Young Children | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html

  Nirsevimab is a monoclonal antibody that prevents severe RSV disease and is recommended for infants and some young children. […] Healthcare providers should discuss both the RSV maternal vaccine (Pfizers Abrysvo) and nirsevimab with parents and consider patient preferences when deciding which product is best for their family. […] Nirsevimab is recommended for infants younger than 8 months of age who are born during or are entering their first RSV season (typically fall through spring) if: The mother did not receive RSV vaccine during pregnancy, or The mothers RSV vaccination status is unknown, or The infant was born within 14 days of maternal RSV vaccination. […] Providers should talk to parents and recommend nirsevimab for eligible babies. […] Nirsevimab is recommended for some children (ages 8 through 19 months) who are at increased risk for severe RSV disease and entering their second RSV season.

• #1 RSV Immunization Guidance for Infants and Young Children | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html

  Nirsevimab should be administered October through the end of March in most of the continental United States. […] Nirsevimab is a monoclonal antibody recommended to children for the prevention of severe RSV disease. It is not a vaccine. RSV vaccines (GSK’s AREXVY, Pfizer’s ABRYSVO, and Moderna’s mResvia) have been approved for adults but are NOT approved for use in infants or young children. […] Early real-world data show that nirsevimab was at least 80-90% effective in preventing babies from being hospitalized with RSV. […] Nirsevimab and routine childhood vaccines can be administered during the same visit. No interval between nirsevimab and live vaccines (such as measles, mumps, and rubella [MMR] and varicella) is necessary.

• #1

  https://www.aurorahealthcare.org/services/primary-care/preventive-care/vaccinations/rsv-vaccine

  Pregnant people between 32 and 36 weeks are also eligible for Abrysvo, which offers protection to them and their unborn baby. […] Babies eight months and younger who were born during or are entering their first RSV season should get the RSV antibody treatment. […] Babies and toddlers 8 to 19 months old who have an increased risk of RSV complications and are entering their second RSV season may also be eligible. […] If their mother receives the RSV vaccine while pregnant, infants are already protected against severe RSV and wont need to get the antibody treatment once born. […] The RSV antibody treatment is most often administered to babies between October and March. Even though the RSV shot is a newly approved treatment and hasnt been a standard vaccine until now, its recommended for all infants.

• #1 Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html

  RSV immunizing products are optimally administered just before the start of the RSV season. […] A single dose of nirsevimab is administered to infants. […] The protective efficacy of RSVpreF (AbrysvoTM) takes some time to develop; therefore, it is optimally administered at least 2 weeks before birth to allow for the transplacental transfer of protective antibodies. […] RSVpreF vaccine administered to pregnant women and pregnant people results in a reduction in RSV associated hospital admission in their infants by 57%. […] All RSV vaccines provide good protection against medically attended RSV respiratory tract infections (RTI) for adults 60 years of age and older. […] A single dose of RSV vaccine is recommended for adults 75 years of age and older, especially those at increased risk, as well as for adults 60 years of age and older who are residents of nursing homes and other chronic care facilities. […] To reduce morbidity and mortality associated with RSV infection in older adults, a single dose of RSV vaccine, either RSVPreF3, RSVpreF, or mRNA-1345, is recommended for adults 75 years of age and older, particularly older adults at increased risk of severe RSV disease.

• #1 RSV (Respiratory Syncytial Virus) Preventive Antibody Immunization Information Statement | CDC

  https://www.cdc.gov/vaccines/vpd/rsv/immunization-information-statement.html

  A respiratory syncytial virus (RSV) preventive antibody can prevent severe lung disease caused by RSV. […] The RSV preventive antibody (generic name nirsevimab, trade name Beyfortus) is a shot that prevents severe RSV disease in infants and young children. […] Infants born during the RSV season (typically fall through spring) should receive a single dose of the RSV Immunization within 1 week after birth. […] Some infants and young children who are at increased risk for severe RSV disease may need a single dose of the RSV antibody before or during their second RSV season. […] RSV preventive antibodies can be given at the same time as vaccines routinely recommended for infants and young children.

• #1 Our ambition to improve RSV care for infants

  https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus.html

  RSV is a very common, contagious seasonal virus that is easily transmissible from person to person through respiratory droplets, for example through coughing or sneezing.3 While most babies with RSV will only experience mild, cold-like symptoms, serious cases of RSV can have a significant impact and even be life-threatening.3 […] At AstraZeneca, we want to ensure not only that infants around the world have access to currently available management options, but that we are also following the science and working tirelessly to achieve improved RSV care and management that involves prevention, diagnosis and earlier treatment. […] There is currently no specific treatment for Respiratory syncytial virus (RSV), meaning that prevention is key for infants.4 […] Looking to the near future, there are therapeutic options that offer hope with recent scientific advancements in the RSV field, families might soon start to see a range of different options offering immunity to all infants and therefore providing protection against RSV. […] The prevention of RSV morbidity and mortality remains a global health care priority.17 No parent or family should have to experience their child struggle with RSV infection, and its our responsibility as a scientific community to follow the science and develop new solutions.

• #1 Respiratory syncytial virus (RSV) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/respiratory-syncytial-virus/diagnosis-treatment/drc-20353104

  Treatment for respiratory syncytial virus generally involves self-care measures to make your child more comfortable (supportive care). But hospital care may be needed if severe symptoms occur. […] If the RSV infection is severe, a hospital stay may be necessary. Treatments at the hospital may include: […] An inhaler (bronchodilator) or steroids are not proved to be helpful in treating RSV infection. […] FDA approves first vaccine for pregnant individuals to prevent RSV in infants. […] FDA grants vaccine approval for moms-to-be to prevent RSV in newborns.

• #1 RSV Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/rsv-respiratory-syncytial-virus

  RSV is a respiratory infection caused by a virus. Babies can get a monoclonal antibody treatment to help protect them. Theres a vaccine available for adults over 60 and pregnant women. […] Theres no specific treatment for RSV. If you or your child has severe RSV, you may need to stay in the hospital to recover. There, providers might help you get better with: Oxygen therapy to get more oxygen into your body, Fluids through an IV to prevent dehydration, Mechanical ventilation (a ventilator) if you cant breathe on your own. […] Babies up to 8 months old and some toddlers at high risk can get a monoclonal antibody immunization. This gives them antibodies that can help them fight off an RSV infection. Pregnant women and adults 75 and older (or 60 and older with certain health conditions) are eligible for RSV vaccines.

• #1

• #1 Vaccination Amid Limited RSV Therapy Options for Adults

  https://www.pharmacytimes.com/view/vaccination-amid-limited-rsv-therapy-options-for-adults

  When we think about treatment, obviously vaccine is one of the best ways to be proactive, but not every patient is going to be there. One of the things you want them to understand is there arent many great treatments for RSV [respiratory syncytial virus] if youre not proactive and being more preventative in your strategies. […] So aerosolized ribavirin therapy has been utilized, but just by saying that out loud, I think we all realize that this is a cumbersome therapy to have to administer to patients. It is expensive. Its associated with fairly significant toxicities. Other therapies that have been utilized include steroids, corticosteroids maybe. Intravenous immunoglobulins have been trialed as well. […] But again, for adults, [there are] not a whole lot of fantastic options available.

• #1 Beyfortus Provides RSV Protection for Kids | Johns Hopkins | Bloomberg School of Public Health

  https://publichealth.jhu.edu/2023/beyfortus-provides-rsv-protection-for-kids

  For that, youd need a vaccine. There are RSV vaccines currently available for adults over age 60, and experts hope to see general and pediatric vaccines available very soon. […] Prevention is essential because RSV-specific treatments dont exist. […] RSV season is around the corner, so parents should check with their childs pediatrician about nirsevimab.

• #1 Expert Insights on Advances in RSV Prevention and Treatment – NFID

  https://www.nfid.org/expert-insights-on-advances-in-rsv-prevention-and-treatment/

  There are a number of RSV vaccine candidates coming down the pike for children, pregnant women, and adults, that we hope will see the light of day very soon. There also are monoclonal antibodies that exist now for prevention in the highest-risk populations, primarily in premature infants under 29 weeks of age. […] New and innovative tools to prevent and treat RSV have the potential to significantly reduce the burden of disease in young children and older adults in the US. Successful implementation of these tools will rely on raising awareness about RSV and the burden of disease, and on appreciation of the benefits of prevention.

• #1

  https://link.springer.com/article/10.1007/s40121-024-00939-w

  Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting in substantial morbidity and mortality. […] This study modeled the public health impact of vaccinating older adults in the United States with the adjuvanted RSVPreF3 vaccine. Vaccination was given once at the start of the analysis and the impact was assessed over 3 years. […] Assuming the same vaccination coverage as for influenza vaccines, adjuvanted RSVPreF3 vaccination was estimated to prevent nearly 3 million symptomatic RSV cases over 3 years, including over 1.5 million outpatient visits, over 200,000 hospitalizations, and nearly 17,000 deaths compared with no vaccination. […] Vaccinating adults aged 60 years and older with the adjuvanted RSVPreF3 vaccine provides substantial public health benefits in the United States.

• #1 RSV vaccine, antibody treatment could reduce ICU encounters | CIDRAP

  https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-antibody-treatment-could-reduce-icu-encounters

  The results suggest that efforts to increase availability and acceptance of these therapies are warranted. […] In a commentary on the study, two Spanish researchers said the study’s findings „support the mounting evidence that the recently licensed RSV preventive strategies may substantially change the epidemiology of RSV bronchiolitis and associated health care system utilization as we currently know it.”

• #1 Learn More: What You Need to Know about RSV Vaccines for Older Adults (60+) | HealthInAging.org

  https://www.healthinaging.org/tools-and-tips/learn-more-what-you-need-know-about-rsv-vaccines-older-adults-60

  If you get the RSV vaccine, some possible side effects include: Pain, redness, or swelling in the location where you received the shot. Tiredness, aches in your body or joints, fever, nausea, or diarrhea after receiving the shot. Most people who get an RSV shot do not have any serious problems with it. Most side effects are mild and usually go away within a few days. […] RSV vaccination is currently recommended as a single lifetime dose only. […] RSV vaccines are covered by Medicare Part D, but they may not be currently covered by Medicare Part B. Private insurers can individually decide whether to cover the RSV vaccine. […] RSV is a serious disease, especially for older adults. It causes an infection of the lungs similar to the flu. Most cases of serious RSV are found in older adults, and older adults who get RSV are at greater risk of hospitalization or even death.

• #1 The new RSV shot for babies: What parents need to know – Harvard Health

  https://www.health.harvard.edu/blog/the-new-rsv-shot-for-babies-what-parents-need-to-know-202309082971

  These antibodies can prevent or lessen the severity of an RSV infection. […] One dose of nirsevimab is recommended for all babies under the age of 8 months as close to the start of RSV season as possible. […] The new shot is also recommended for children 8 to 19 months with conditions that put them at high risk of becoming very sick if they get RSV. […] Infants and toddlers who get nirsevimab do not need to get monthly shots of palivizumab as well. […] Because this is brand new, there may be some challenges with getting it to all the infants and toddlers that are eligible.

• #1 RSV Immunization | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/infectious-disease/rsv-immunization

  Adults age 60 and older can receive the RSV vaccine using a shared decision model through which the decision to be vaccinated is made on an individual level and informed by a decision process between the health care provider and the patient. […] It is recommended that pregnant individuals receive the RSV immunization between week 32 and week 36 of the pregnancy. Vaccination during pregnancy provides important protections for infants, which is particularly important since the U.S. is experiencing shortages of the RSV immunization that is recommended for children. […] Newborn infants who weigh less than 11 pounds and are younger than 6 months of age are at highest risk and are encouraged to get the RSV immunization. […] The Centers for Disease Control and Prevention (CDC) has directed providers to prioritize this RSV immunization dosage for children at highest risk for serious illness from RSV.

• #1 Respiratory syncytial virus vaccine development

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3255794/

  Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract viral disease in infants and young children. Presently, there are no explicit recommendations for RSV treatment apart from supportive care. […] Clearly, further development of RSV vaccines and therapies is warranted, and novel successful products could have an enormous positive impact on human health. […] A new strategy for RSV control involving siRNA is now in early stages of clinical development. […] As prophylaxis for RSV infection, a monoclonal antibody against a highly conserved RSV F epitope has been used (Synagis/palivizumab [MedImmune, Gaithersburg, MD, USA]). This antibody has significantly reduced severe disease in high-risk infants. […] A new product with a similar specificity was recently developed by MedImmune (motavizumab) to replace Synagis/palivizumab, but tests did not support superiority and development of the new product for licensure has been discontinued.

• #1 RSV vaccine: new protection options | Northwell Health

  https://www.northwell.edu/news/insights/rsv-vaccine-for-adults-pregnant-women

  Respiratory syncytial virus (RSV) has made a fair amount of news in recent years as a cause of several nationwide outbreaks, but the development of a vaccine for this strange-sounding virus has been in the works for decades. Thankfully, as of 2024, the approval of three vaccines and a new monoclonal antibody treatment have signaled a new era of RSV protection. […] Experts say the suite of new options could significantly decrease the rate of severe infection in children. The rate of hospitalization of children due to RSV should fall by at least 50%, says Lorry Rubin, MD, director of pediatric infectious disease at Northwell. And when the immunization program is mature, I would expect a 90% decrease in RSV hospitalization rate. […] Three RSV vaccines are FDA-approved for use. The Food and Drug Administration approved two RSV vaccines in 2023, starting in May with the vaccine AREXVY. This vaccine is adjuvanted meaning it offers a stronger immune response and it is recommended for all persons age 75 years and older. It is also recommended for those 60-74 with underlying conditions that put them at increased risk for serious RSV disease.

• #1 The RSV roadmap in children: Lessons learned, paths forward | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/91/9_suppl_1/S19

  Direct antiviral treatments have similarly had a poor impact with few exceptions. […] Immunoglobulins are broadly used for prophylaxis against RSV bronchiolitis. Due to the stymied development of RSV vaccines, immunoglobulins were explored as passive prophylaxis to neutralize viral particles prior to infection. […] Recognition of the immunogenicity of the prefusion form of the F protein prompted development of the monoclonal antibody, nirsevimab. Nirsevimab has been demonstrated to be efficacious in reducing medically attended RSV by 79%, hospitalization due to RSV by 80.6%, and RSV lower respiratory tract infection associated with ICU admission by 90%. […] RSV continues to be a formidable pathogen for infants and young children. While select RSV vaccines have exhibited encouraging outcomes in adults and by way of maternal immunization, challenges remain in developing a safe and effective vaccine that provides long-lasting protection in the youngest age groups who remain vulnerable to severe RSV infection. The overall limited efficacy of RSV treatments is also noteworthy. Supportive care remains the mainstay of treatment for all children. Still, recent advances in prevention of disease have the potential to substantially change the impact of this pathogen.

• #1 RSV Recommendations and Guidance | Johns Hopkins | Bloomberg School of Public Health

  https://publichealth.jhu.edu/2024/rsv-recommendations-and-guidance

  Three RSV vaccines are approved for use in the U.S. in adults ages 60 and older: GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia. […] One dose of RSV vaccine provides protection against severe RSV disease in adults ages 60 years and older for up to two years, meaning people do not need to get a dose every RSV season. […] In clinical trials, Arexvy and Abrysvo were 78% effective in preventing severe RSV over a second year, according to the CDC, while mRESVIA showed 50% efficacy in preventing RSV after 18 months. […] RSV infections can be severe for babies and older adults, but these safe, effective vaccines can help prevent the worst outcomes.

• #1

  https://www.advocatehealth.com/health-services/primary-care/preventive-care/vaccinations/rsv-vaccine

  Talk with your health care provider about getting RSV shots or treatment for yourself or your child. […] Because the RSV immunization is offered to pregnant people, many infants may already be protected against severe RSV. Its advised that most babies get this childhood immunization while in utero or from the antibody treatment after birth, but not both. […] Even though the RSV shot is a newly approved treatment and hasnt been a standard vaccine until now, its recommended for all infants. Its safe for your child to get their RSV antibody treatment with other childhood immunizations. […] The RSV vaccine for adults has been shown to be effective for two RSV seasons, but research is still ongoing. Recommendations may shift as more data is available. […] The RSV antibody treatment for most infants is effective at protecting against severe RSV for one season. After that time, your childs immune system will be strong enough to fight infections on its own.

• #1 RSV Prevention and Treatment | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/rsv/treatment

  A vaccine during pregnancy or preventive antibody is now available. Help prevent RSV before it happens. […] The CDC recommends RSV vaccination for all adults ages 75 years or older, and for adults ages 60-74 who are at increased risk of severe RSV. […] There are currently three licensed RSV vaccines for adults 60 or older. […] The CDC has recommended two new ways to help protect your baby from severe RSV illness: A preventative antibody is recommended for all babies younger than 8 months old and born during or entering their first RSV season. […] Receiving an RSV vaccination during pregnancy. This vaccine should be received if you are 32-36 weeks pregnant during RSV season (September through January). […] In severe cases, most commonly for infants younger than 6 months of age and older adults, hospitalization may be needed. The hospital will use intravenous (IV) fluids to aid in hydration, and a breathing machine or humidified oxygen to help your body receive the oxygen it needs.

• #1 Respiratory Syncytial Virus Prefusion F (RSVPreF3) Vaccine – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK594261/

  Respiratory syncytial virus (RSV) is a prevalent respiratory pathogen that primarily affects infants, young children, older adults, and individuals with compromised immune systems. The U.S. Food and Drug Administration (FDA) approved the first vaccines against RSV in 2023. The recombinant subunit RSV prefusion F3 (RSVPreF3) vaccine contains the RSV F glycoprotein stabilized in its prefusion (pre-F) state. By targeting the pre-F glycoprotein, the vaccine stimulates the production of neutralizing antibodies, activates both humoral and cellular immune responses, and promotes the formation of memory B and T cells. This activity provides comprehensive information on the indications, administration, dosage recommendations, mechanism of action, monitoring, adverse reactions, precautions, and contraindications associated with RSVPreF3 vaccines. This activity empowers healthcare teams to identify patients at high risk of severe RSV infection outcomes and to recommend and administer the RSVPreF3 vaccine according to nationally accepted guidelines.

• #1

  https://link.springer.com/article/10.1007/s40121-024-00939-w

  In 2023, two vaccines were approved by the US Food and Drug Administration (FDA) for the prevention of LRTD caused by RSV in individuals 60 years of age and older: the adjuvanted RSVPreF3 vaccine (Arexvy, GSK) and the RSVpreF vaccine (Abrysvo, Pfizer). […] The objective of this study was to estimate the public health impact of RSV vaccination with the adjuvanted RSVPreF3 vaccine compared with no vaccination in US adults aged 60 years. […] The current analysis estimates substantial public health benefits associated with the adjuvanted RSVPreF3 vaccine for the prevention of RSV cases and RSV-related morbidity and mortality in US adults aged 60 years. […] This vaccine provides the opportunity to avoid nearly 3 million symptomatic RSV-ARI cases in US older adults over a 3-year period, which would have a considerable impact on associated morbidity and mortality.

• #2 New Monoclonal Antibody and Vaccine Can Protect Kids from RSV > News > Yale Medicine

  https://www.yalemedicine.org/news/new-rsv-monoclonal-antibody-vaccine-for-kids

  Two new immunizations may help block a virus that overwhelmed childrens hospitals last year. The first is a monoclonal antibody called nirsevimab (brand name: Beyfortus) that targets all infants up to 8 months old, born during or entering their first RSV season, and for a small group during their second season if they are between 8 and 19 months old and at high risk for severe disease (including children who are severely immunocompromised). […] The second is a vaccine called Abrysvo to be given during the RSV season to pregnant individuals so they can pass along protection to the fetus and prevent severe RSV disease in newborn infants. […] Nirsevimab should reduce hospitalizations. Even if it doesn’t completely prevent infection, we expect it will reduce disease severity significantly. […] The CDC approvals of nirsevimab in July and the vaccine for pregnant women in September came weeks after the CDC finalized two new RSV vaccines for adults ages 60 and older.

• #2 Should You Get an RSV Vaccine? > News > Yale Medicine

  https://www.yalemedicine.org/news/should-you-get-an-rsv-vaccine

  In September 2023, the CDC approved ABRYSVO on a seasonal basis to provide pregnant women with antibodies they could pass along to the fetus and protect their newborn babies from birth to 6 months of age from severe RSV. […] The vaccine is available from September to January to provide protection of newborns when infection rates are expected to be at their highest, between October and March. […] ABRYSVO has been shown to reduce the risk of RSV hospitalization for babies by 57% in the first six months after birth, according to the CDC. […] Nirsevimab, which was developed by Sanofi and AstraZeneca, is given in a single injection to the thigh. […] A Phase 3 clinical trial showed that nirsevimab reduced RSV-triggered lower respiratory tract infections serious enough to require medical care by 76.4% and cut RSV hospitalizations in healthy full-term and near-full-term infants by 76.8%.

• #2 RSV: Symptoms & Treatment | Kaiser Permanente

  https://healthy.kaiserpermanente.org/oregon-washington/health-wellness/rsv

  People ages 75 and older, pregnant people (from September through January), and people ages 60-74 who are at increased risk of severe RSV should get the RSV vaccine. […] Yes, the RSV vaccine is safe and effective. The most common side effects include pain at the injection site, fatigue, headache, and muscle or joint pain. […] Nirsevimab (also known as Beyfortus) is a type of medicine known as an antibody. It provides immediate, short-term protection from RSV disease. […] Nirsevimab isn’t technically a vaccine. It’s an injection that provides protection against RSV. […] According to the CDC, nirsevimab reduces the risk of severe RSV disease by about 75%. One dose of nirsevimab protects infants for at least 5 months.

• #2 Update: What RSV preventatives mean for those with PI | Immune Deficiency Foundation

  https://primaryimmune.org/resources/news-articles/update-what-rsv-preventatives-mean-those-pi

  Importantly, none of the three vaccines contain live virus (or even whole virus), so they cannot cause RSV infections in individuals with PI. […] Abrysvo and Arexvy are protein subunit vaccines that contain a piece of RSV meant to provoke an immune responsein this case, a protein found on the virus surface that helps RSV infect human cells. […] In phase III clinical trials, Arexvy was 82.6% effective at preventing lower respiratory tract infections from RSV in adults aged 60 and older during their first RSV season after vaccination. […] mRESVIA was 83.7% effective in preventing lower respiratory tract infections from RSV in older adults during the first RSV season after vaccination. […] Recently, GlaxoSmithKline published additional analysis of Arexvy in those 60 and older with at least one chronic condition placing them at high risk of severe RSV.

• #2

  https://www.aurorahealthcare.org/services/primary-care/preventive-care/vaccinations/rsv-vaccine

  Pregnant people between 32 and 36 weeks are also eligible for Abrysvo, which offers protection to them and their unborn baby. […] Babies eight months and younger who were born during or are entering their first RSV season should get the RSV antibody treatment. […] Babies and toddlers 8 to 19 months old who have an increased risk of RSV complications and are entering their second RSV season may also be eligible. […] If their mother receives the RSV vaccine while pregnant, infants are already protected against severe RSV and wont need to get the antibody treatment once born. […] The RSV antibody treatment is most often administered to babies between October and March. Even though the RSV shot is a newly approved treatment and hasnt been a standard vaccine until now, its recommended for all infants.

• #2 Should You Get an RSV Vaccine? > News > Yale Medicine

  https://www.yalemedicine.org/news/should-you-get-an-rsv-vaccine

  ABRYSVO is also approved for administering to pregnant women ahead of the RSV season to provide them with antibodies they could pass along to the fetus and protect their newborns from birth to 6 months of age from severe RSV. […] Both the AREXVY and ABRYSVO vaccines for older adults use traditional platforms similar to a flu shot. […] The third vaccine, mRESVIA, from Moderna, uses an mRNA platform, similar to the company’s COVID vaccine. […] AREXVY was the first to receive Food and Drug Administration (FDA) approval in May 2023 based on data from a trial conducted by the company in the U.S. and internationally. […] ABRYSVO, also approved in May 2023, showed an efficacy of almost 89% against LRTD involving at least three symptoms in the first year after vaccination. […] mRESVIA, was approved in May 2024 after Moderna provided trial clinical trial data showing an efficacy against LRTD of 83.7%.

• #2 RSV vaccines: Questions patients may have and how to answer | American Medical Association

  https://www.ama-assn.org/delivering-care/public-health/rsv-vaccines-questions-patients-may-have-and-how-answer

  Respiratory syncytial virus (RSV) season often starts in the fall and peaks in winter. RSV vaccines are available to help reduce risk for severe illness. […] The first vaccines for RSV were licensed by the Food and Drug Administration (FDA) in 2023 for older adults. There are now three RSV vaccines recommended for those 75 or older and for adults 60-74 years old who are at increased risk of severe RSV disease. […] RSV generally causes mild upper respiratory disease in healthy adults. But for adults 60 or older with certain underlying conditions or other risk factors, RSV can cause serious illness. […] For now, only one dose of the RSV vaccine is recommended. So far, RSV vaccines appear to provide some protection for at least two RSV seasons. […] Vaccination should occur before the onset of the fall and winter RSV season.

• #2 Learn More: What You Need to Know about RSV Vaccines for Older Adults (60+) | HealthInAging.org

  https://www.healthinaging.org/tools-and-tips/learn-more-what-you-need-know-about-rsv-vaccines-older-adults-60

  The RSV vaccine has both harms and benefits. […] Getting an RSV shot can provide the following benefits: You are less likely to get RSV. If you do get RSV, you are less likely to get seriously sick. You are less likely to be hospitalized with RSV. […] Potential harms of getting an RSV shot include: A small number of people experienced serious inflammatory neurological events after receiving the vaccine. However, the majority of people who have received the RSV vaccine did not experience those harms. […] Your healthcare professional will help you weigh whether the benefits of the vaccine outweigh the harms. […] There are some cautions about when to take the RSV vaccine: If you have ever been allergic to any of the ingredients in the RSV vaccine, you should not get the RSV shot. If you are currently sick (whether or not you have a fever), you should wait to get the RSV shot until you are feeling better.

• #2 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  Adults aged 60–74 years who do not have a risk factor for severe RSV disease can consider a single dose of RSV vaccine. […] A single dose of RSV vaccine is recommended for all Aboriginal and Torres Strait Islander adults aged ≥60 years. […] A single dose of RSV vaccine is recommended for adults aged ≥60 years with risk factors for severe RSV disease. […] A single dose of Abrysvo is recommended for pregnant women at 28–36 weeks gestation to protect the infant. […] Maternal immunisation reduces the risk of severe RSV disease in infants <6 months of age by around 70%. [...] Nirsevimab is preferred over palivizumab. [...] The dose of nirsevimab for older children entering their 2nd RSV season is 200 mg, given as 2 intramuscular injections at 2 different sites during the same visit. [...] The dose of palivizumab is 15 mg/kg, each month, given by intramuscular injection up to 5 times during the RSV season.

• #2 RSV Recommendations and Guidance | Johns Hopkins | Bloomberg School of Public Health

  https://publichealth.jhu.edu/2024/rsv-recommendations-and-guidance

  Three RSV vaccines are approved for use in the U.S. in adults ages 60 and older: GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia. […] One dose of RSV vaccine provides protection against severe RSV disease in adults ages 60 years and older for up to two years, meaning people do not need to get a dose every RSV season. […] In clinical trials, Arexvy and Abrysvo were 78% effective in preventing severe RSV over a second year, according to the CDC, while mRESVIA showed 50% efficacy in preventing RSV after 18 months. […] RSV infections can be severe for babies and older adults, but these safe, effective vaccines can help prevent the worst outcomes.

• #2 RSV (Respiratory Syncytial Virus) Vaccines

  https://www.webmd.com/lung/rsv-vaccines

  Pregnant people can get a single dose of the RSV vaccine known as Abrysvo. […] The RSV vaccine may have some side effects, but not in everyone who gets it. […] According to the CDC, the most common side effects from the RSV vaccine were: Pain, Redness, Swelling where the needle goes in, Headache, Nausea, Diarrhea, Muscle/joint pain, Fatigue, Fever. […] In initial clinical trials, GSK, the company that makes Arexvy, reported that it was 82.6% effective against lower respiratory tract disease during the first season, 77.3% effective during the middle of the season, and 67.2% effective over two seasons. […] If youre pregnant or over the age of 60 and RSV season is coming up, talk to your doctor or health care professional to see if you should get the shot.

• #2 Respiratory Syncytial Virus (RSV) Vaccine Safety | Vaccine Safety | CDC

  https://www.cdc.gov/vaccine-safety/vaccines/rsv.html

  Based on available data, ACIP and CDC continue to conclude that the benefits of RSV vaccination, by reducing RSV-associated hospitalizations and deaths, outweigh the potential risk for GBS among adults 75 and older and among adults 60 to 74 years old at increased risk of severe RSV disease. […] The Advisory Committee on Immunization Practices (ACIP) judged the benefits of maternal Pfizer RSV (Abrysvo) vaccination at 32 to 36 weeks’ gestation to outweigh potential risks. […] CDC and FDA continue to monitor and communicate about the safety of maternal RSV vaccination to ensure the benefits of vaccination outweigh possible risks.

• #2 RSV Vaccines | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/index.html

  RSV vaccines are recommended for all adults ages 75 and older and adults ages 60 74 who are at increased risk for severe RSV. […] There are two immunizations recommended to protect infants from severe RSV: a maternal RSV vaccine (Pfizer’s Abrysvo) given during pregnancy or an RSV antibody given to infants after birth. […] Immunizations to protect against severe RSV – Vaccine for adults ages 60 and over, babies during infancy, including vaccine given to mother during pregnancy.

• #2

  https://health.maryland.gov/carroll/Pages/Flu-COVID-19-RSV-Vaccines.aspx

  Vaccination against flu, COVID-19, and RSV is the best way to reduce your risk of severe illness from these viruses. Learn more about vaccines for respiratory illness. […] The RSV vaccine is recommended for certain groups: […] If you are pregnant and have not had the RSV vaccine before, get the RSV vaccine (Pfizer’s Abrysvo) if you are between 32 and 36 weeks pregnant from September through January. This will protect your baby during their first 6 months, when they are at highest risk of severe illness from RSV. […] If you do not get the RSV vaccine during pregnancy, your baby should get an RSV antibody treatment if they are younger than 8 months shortly before the RSV season, or within one week of their birth if born October – March. […] The RSV antibody treatment is also recommended for some children aged 8 months to 19 months at increased risk for severe RSV disease.

• #2 RSV Symptoms, Treatment & Vaccines | University Hospitals | University Hospitals

  https://www.uhhospitals.org/services/rsv-treatment-services

  A shot that contains RSV antibodies (Beyfortus) can be given to babies, which will protect them against the illness for several months. It is recommended for babies younger than 8 months and should be administered just before or during the RSV season. […] The CDC recommends an RSV vaccine to everyone ages 75 and older and for adults ages 6074 who are an increased risk of severe RSV illness. […] In the most severe cases, a person may require hospitalization. In the hospital the patient may require supplemental oxygen, intravenous (IV) fluids to combat dehydration, and mechanical ventilation.

• #2

• #2 RSV vaccines: Questions patients may have and how to answer | American Medical Association

  https://www.ama-assn.org/delivering-care/public-health/rsv-vaccines-questions-patients-may-have-and-how-answer

  Flu, COVID-19 and RSV vaccines may be given at the same visit. […] As with other vaccines, patients can expect some side effects from RSV vaccination. Some of the common side effects include fatigue, fever, headache, muscle or joint pain, nausea and diarrhea. […] Two immunization products are available for the prevention of severe RSV disease in infants. The maternal RSV vaccine (Pfizer’s Abrysvo) is given during weeks 32 through 36 of pregnancy during September through January in most of the U.S. Maternal antibodies protect the baby against RSV for approximately 6 months after birth. […] Nirsevimab is a single shot that is long lasting and can be given with other age-appropriate childhood vaccines. […] For infants born during or entering their very first RSV season, nirsevimab was 79% effective against RSV medically attended lower respiratory tract illness and 80% effective at preventing hospitalization. […] Both vaccines for older adults are also extremely effective at preventing serious illness from RSV infection. […] Most private health insurers must cover these immunization products without cost sharing. Medicare Part D covers all vaccines that the ACIP recommends, including vaccine for RSV.

• #2 Treatment and prophylaxis of respiratory syncytial virus (RSV) disease – Scientific guideline | European Medicines Agency (EMA)

  https://www.ema.europa.eu/en/treatment-prophylaxis-respiratory-syncytial-virus-rsv-disease-scientific-guideline

  The guideline covers the clinical development of vaccines and monoclonal antibodies for the prevention of RSV disease and direct acting antiviral agents (DAAs) for the treatment of RSV disease. […] The guideline also addresses vaccination of pregnant women with the aim of preventing RSV disease in their infants. […] The draft guideline proposes some considerations on nonclinical investigations of efficacy and risk of vaccine-associated enhanced disease to support clinical trials with preventive or therapeutic products directed at RSV. […] This concept paper proposes the development of a guideline on the clinical evaluation of medicinal products indicated for the treatment and prophylaxis of respiratory syncytial virus (RSV) infections for which there is no regulatory guidance currently available in the EU.

• #2 Our ambition to improve RSV care for infants

  https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus.html

  RSV is a very common, contagious seasonal virus that is easily transmissible from person to person through respiratory droplets, for example through coughing or sneezing.3 While most babies with RSV will only experience mild, cold-like symptoms, serious cases of RSV can have a significant impact and even be life-threatening.3 […] At AstraZeneca, we want to ensure not only that infants around the world have access to currently available management options, but that we are also following the science and working tirelessly to achieve improved RSV care and management that involves prevention, diagnosis and earlier treatment. […] There is currently no specific treatment for Respiratory syncytial virus (RSV), meaning that prevention is key for infants.4 […] Looking to the near future, there are therapeutic options that offer hope with recent scientific advancements in the RSV field, families might soon start to see a range of different options offering immunity to all infants and therefore providing protection against RSV. […] The prevention of RSV morbidity and mortality remains a global health care priority.17 No parent or family should have to experience their child struggle with RSV infection, and its our responsibility as a scientific community to follow the science and develop new solutions.

• #3 Respiratory Syncytial Virus (RSV): The Disease, Vaccines & Monoclonal Antibody | Children’s Hospital of Philadelphia

  https://www.chop.edu/vaccine-education-center/vaccine-details/rsv-vaccine-monoclonal-antibody

  Pregnant people can get a single dose of the RSV vaccine known as Abrysvo during weeks 32 through 36 of pregnancy if that period of gestation occurs during RSV season, which for much of the United States means from September through January. […] All infants younger than 8 months of age, including those born during RSV season, are recommended to get one dose of the RSV monoclonal antibody known as nirsevimab (Beyfortus). […] In clinical trials, a single dose of either protein-based RSV vaccine for adults prevented RSV infections associated with the lower respiratory tract in about 70 to 90 of 100 vaccine recipients. […] In clinical trials, a single dose of the RSV vaccine administered during pregnancy reduced the risk of an RSV infection leading to hospitalization during the first six months of life in 57 of 100 infants born to vaccinated individuals.

Zobacz więcej